| abstract |
REFERS TO COMPOUNDS DERIVED FROM IMIDAZO [1,2-a] PYRIDINE OF FORMULAS (I) O (II) WHERE m IS 1 O 4; R20 IS H, HALO, (C1-C6) ALKYL, CN, AMONG OTHERS; R1 IS HALO OR (C1-C6) ALKYL; R11 IS H, HALO, OR (C1-C6) ALKYL; L1 IS A LINK, -NH- OR -C (= O) NH-; R2 IS R3 OR L2R3, WHERE R3 IS CYCLOALKYL (C3-C8) OPTIONALLY SUBSTITUTED; L2 IS -NH-, AMONG OTHERS. PREFERRED COMPOUNDS ARE: N- {5- [3- (3,3-DIFLUOROCYCLBUTIL) -1,2,4-OXADIAZOL-5-IL] -2-METHYLPHENYL} IMIDAZO [1,2-a] PYRIDINE-3-CARBOXAMIDE ; N- {2-METHYL-5- [5- (3-OXOCYCLOPENTIL) -1,2,4-OXADIAZOL-3-IL] PHENYL} IMIDAZO [1,2-a] PYRIDINE-3-CARBOXAMIDE; N- {5- [5- (3-HYDROXY-3-METHYL CYCLOBUTYL) -1,2,4-OXADIAZOL-3-IL] -2-METHYLPHENYL} IMIDAZO [1,2-a] PYRIDINE-3-CARBOXAMIDE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF PDGFR KINASES OR c-KIT, BEING USEFUL IN THE TREATMENT OF ASTHMA, ALLERGIC RHINITIS, PULMONARY FIBROSIS, SCLERODERMIA |